By the Numbers

Up-in-coupon continues to lead the way for MBS returns

| October 15, 2021

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors. This material does not constitute research.

Conventional 30-year MBS have outperformed hedges over the last three months, according to the Bloomberg Barclays MBS Index. Excess returns started improving in August with coupons 4.0% and higher leading the way. The outperformance subsequently spread to 3.0%s and 3.5%s. Ginnie Mae MBS have also generated positive excess returns across the coupon stack since August. But Ginnies have not favored higher coupons to the same degree as conventionals. Investors may be anticipating that Fed tapering will have a larger effect on conventional MBS than it will on Ginnie Mae MBS.

Conventional and Ginnie Mae 2.5%s have generally performed in-line with hedges for the last few months (Exhibit 1). The graphs plot cumulative excess returns starting from July 1. However conventional 2.0%s have generally underperformed hedges. This was true of Ginnie Mae 2.0%s until August, after which performance began to improve. And Ginnie 2.0%s returns jumped markedly in late September. Meanwhile conventional 3.0%s and 3.5%s have performed much better than Ginnie Mae MBS, although even the Ginnies have generated positive excess returns over the last month. Of course, these returns do not reflect gains from persistently special dollar rolls in lower coupons.

Exhibit 1. Conventional MBS excess returns have favored higher coupons  

Excess returns reported by the Bloomberg Barclays MBS index. Excess returns are cumulative starting July 1.
Source: Bloomberg, Amherst Pierpont Securities

Option-adjusted spreads show a similar story. Conventional and Ginnie Mae OASs have been nearly identical in the 2.5% coupon. But Ginnie 2.0% OASs have tightened more than conventional OASs over the last few months. Ginnie 3.5% OASs were roughly the same as conventional OASs at the start of July but are now roughly 15 bp wider. And Ginnie 3.0% OASs have widened relative to conventionals’ since the beginning of October.

Exhibit 2. Conventional and Ginnie Mae MBS OASs

OASs from Bloomberg’s BAM prepayment model.
Source: Bloomberg, Amherst Pierpont Securities

Conventional investors are likely moving up-in-coupon in preparation for Fed tapering. The Fed is only buying 2.0% and 2.5% 30-year MBS, so those are most likely to weaken when tapering starts. But the shift up-in-coupon has not been as strong in Ginnie Mae MBS. This could be due to net supply, which has been extremely high in conventional MBS but very low in Ginnie Mae MBS. And some investors have fewer investment alternatives to Ginnie Mae MBS, which are backed by the full faith and credit of the US government and carry a 0% risk-weighting for banks.

The recent outperformance has pushed MBS returns positive for the year in coupons 3.0% and higher, although the aggregate index return remains negative due to the heavy weight towards lower coupons (Exhibit 3). And these returns do not reflect dollar rolls, which have traded special in 2.5% and lower coupons. That adds substantially to performance for portfolios that can roll their TBA positions. Excess returns on Ginnie Mae MBS are still negative for the year, despite the recent improvement (Exhibit 4).

Exhibit 3. Conventional MBS excess returns (%)

Excess returns reported by the Bloomberg Barclays MBS index.
Source: Bloomberg, Amherst Pierpont Securities

Exhibit 4. Ginnie Mae MBS excess returns (%)

Excess returns reported by the Bloomberg Barclays MBS index.
Source: Bloomberg, Amherst Pierpont Securities

Brian Landy, CFA
brian.landy@santander.us
1 (646) 776-7795

This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.

Important Disclaimers

Copyright © 2024 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.

In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.

The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.

In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.

Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.

The Library

Search Articles